Preliminary Program: Saturday May 5

8 a.m.-Noon

CME Courses 1-4

8:30 a.m.-5:30 p.m.

Board Review: Passing the OralsCo-Sponsored by McLean Hospital

9 a.m.-4 p.m.

CME Courses 5-10

10 a.m.-5 p.m.

Registration/Course Enrollment Open

APA Resource Center Open

11 a.m.-5 p.m.

Publishers’ Bookfair Open

1 p.m.-5 p.m.

CME Courses 11-14

7 p.m.-10 p.m.

Industry-Supported Symposia

IS1. Sleep: A Window on Mind and Brain Supported by Wyeth-Ayerst Laboratories

A. The Pathogenesis of Narcolepsy and Hypersomnia Emmanuel Mignot, M.D.

B. Influences of Light on Sleep and Mood Barbara L. Parry, M.D.

C. Violent Behaviors Arising from the Sleep Period Mark W. Mahowald, M.D.

D. Sleep Apnea: Why Treat It? Meir H. Kryger, M.D.

E. New Options in the Treatment of Insomnia Milton K. Erman, M.D.

IS2. Advances in the Treatment of Depression in Women: Beyond Clinical Lore Supported by Eli Lilly and Company

A. Gender-Based Differences in the Treatment of Depressed Women Susan G. Kornstein, M.D.

B. Treatment Strategies of PMS/PMDD Teri B. Pearlstein, M.D.

C. Challenges and Opportunities in the Treatment of Childbearing Women Lee S. Cohen, M.D.

D. Critical Issues in Depression and Cognition for Menopausal Women Hadine Joffe, M.D.

IS3. Suicide Risk and Bipolar Disorder: Neurobiology and Treatment Supported by the American Foundation for Suicide Prevention and Solvay Pharmaceuticals, Inc.

A. Clinical Factors Affecting Suicide Risk in Bipolar Disorder Kay R. Jamison, Ph.D.

B. Neurobiology of Suicide and Bipolar Disorder J. John Mann, M.D.

C. Efficacy of Mood Stabilizers in Suicide Prevention Ross J. Baldessarini, M.D.

D. Clinical Management of the Suicidal Bipolar Patient Frederick K. Goodwin, M.D.

E. Evaluation of Suicide Risk in Bipolar Disorder in Children David Shaffer, M.D.

IS4. To Switch or Augment? Contemporary Approaches to Resistant Depression Supported by Pharmacia Inc.

A. Neurological Mechanisms of Treatment Resistance: The Role of Stress Juan F. Lopez, M.D.

B. The Neural Basis of Antidepressant Response and Nonresponse Wayne C. Drevets, M.D.

C. When to Augment Antidepressants Andrew A. Nierenberg, M.D.

D. The Use of Switching in Depression Treatment Charles DeBattista, M.D.

E. The Role of Nonpharmacological Intervention for Treatment-Resistant Depression Lauren B. Marangell, M.D.

IS5. The New Biology of Depression and Antidepressant Treatment Supported by Forest Laboratories Inc.

A. The Depressed Brain Imaged Helen S. Mayberg, M.D.

B. The Neurobiology of Mood Disorders Dennis S. Charney, M.D.

C. What Do Antidepressants Do? Understanding Antidepressant Molecules, Neurotransmitters, and Receptors Pierre Blier, M.D.

D. Healing the Depressed Brain: Signal Transduction and Neural Plasticity Eric J. Nestler, M.D.

IS6. Glucose Control and Diabetes Mellitus During Antipsychotic Treatment Supported by Janssen Pharmaceutica

A. Diagnosis, Classification, and Pathogenesis of Hyperglycemia Harold E. Lebovitz, M.D.

B. Cardiovascular Risk Increases With Glucose Levels Regardless of Diabetes Status Hertzel C. Gerstein, M.D.

C. Antipsychotic-Related Change in Glucose Regulation John W. Newcomer, M.D.

D. Atypical Antipsychotic Agents: Diabetes and Bergman’s Minimal Model Analysis David C. Henderson, M.D.

E. Inhibition of Glucose Transport by Antipsychotic Drugs Donard S. Dwyer, Ph.D.

IS7. PTSD: Clinical Characteristics and Treatment Options Supported by Pfizer Inc.

A. Sympathetic Nervous System Dysregulation in PTSD Steven M. Southwick, M.D.

B. PTSD: Diagnostic Issues and Comorbidity Kathleen T. Brady, M.D.

C. Psychotherapy of PTSD Barbara O. Rothbaum, Ph.D.

D. Advances in the Pharmacotherapy of PTSD Charles R. Marmar, M.D. ▪